Acute myeloid leukemia
Disease and Cancer
EntreMed's ENMD-2076 Active In Solid And Hematological Cancers...2 indication. Phase 1 Leukemia Data Initial data for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the... In this article: Cancer, Ovarian cancer, Leukemia, Medical advice, Revenue, UCLA, Chronic myelogenous leukemia, Antibiotic, and Acute myeloid leukemia |
-
PR Newswire | October 19, 2009
Updated NCCN Guidelines for AML Include Risk Stratification to Assist in Treatment Selection
...to Assist in Treatment Selection The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the...
In this article: National Comprehensive Cancer Network, Cancer, Leukemia, Clofarabine, Decitabine, Acute promyelocytic leukemia, 5-azacytidine, Rare disease, and Genzyme Corporation
-
Boston Globe -- Today's paper A to Z | October 06, 2009
Genzyme must further study drug
NEW YORK - Genzyme Corp. must collect more data on the leukemia drug Clolar before the Food and Drug Administration will consider expanding the use of the therapy to previously untreated adults with acute myeloid leukemia. Based on...
In this article: Genzyme Corp., Food and Drug Administration, Clolar, Cancer, Leukemia, Acute lymphoblastic leukemia, Cambridge, NEW YORK, and Massachusetts
-
Medical News Today | November 16, 2009
Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free
...and 2008. The average age of the patients in this study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from...
In this article: Leukemia, Cancer, University of Minnesota, Medical advice, Chronic myelogenous leukemia, Antibiotic, and Acute lymphoblastic leukemia
-
Miami Herald | September 12, 2009
Naples cardinal: Relic kiss OK despite swine flu
...children, has died of leukemia. Andia Denise Wilson, 30, of Naples, died of acute myeloid leukemia last Tuesday, confirmed Pierre Rutledge, who lives in Miami and heads the Edgerrin James Foundation. Rutledge said Monday that James and...
In this article: Naples, Crescenzio Sepe, Alberto Cutie, Catholic Church, and New Jersey
-
American Cancer Center Online | February 25, 2009
Common Cancer Types
...2006 is 31,890. Leukemia as a cancer type includes acute lymphoblastic (or lymphoid) leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous (or myeloid) leukemia, and other forms of leukemia. It is estimated...
In this article: Cancer, Leukemia, Thyroid cancer, United States, Skin cancer, and American Cancer Society
-
New Kerala | August 03, 2009
New Molecular Markers to help treat AML
...AML Kolkata, Aug 3 : Super Religare Laboratories (SRL), one of India's largest diagnostics network, has launched New Molecular Markers that may stratify the treatment modalities of a person suffering from Acute Myeloid Leukemia (AML). Acute...
In this article: Leukemia, Acute lymphoblastic leukemia, and Neoplasm
-
Wikipedia | September 30, 2009
Acute myeloid leukemia
Acute myeloid leukemia Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow...
In this article: Leukemia, Cancer, Acute promyelocytic leukemia, World Health Organization, Rudolf Virchow, Benzene, Cytarabine, FLT3, and Fatigue
-
Seeking Alpha | September 02, 2009
Genzyme: Near Term Sell, Long Term Buy
...VPHM About this author: On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to...
In this article: Genzyme, Clolar, Revenue, FDA, ViroPharma, TEVA, EU, U.S., and Fabrazyme
-
FDA Advisory Committee To Discuss Genzyme's Clolar For Adult AML On September 1
The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.
In this article: Genzyme Corporation, FDA, Clofarabine, Systemic inflammatory response syndrome, Thrombocytopenia, Leukemia, Capillary leak syndrome, Cancer, and Nausea
Trends
Loading...
More on Acute myeloid leukemia
Description from Wikipedia:
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, resulting in a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of AML remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
Acute myeloid leukemia is a potentially curable disease; but only a minority of patients are cured with current therapy. AML is treated initially with chemotherapy aimed at inducing a remission; some patients may go on to receive a hematopoietic stem cell transplant.
Areas of active research in acute myeloid leukemia include further elucidation of the cause of AML, identification of better prognostic indicators, development of new methods of detecting residual disease after treatment, and the development of new drugs and targeted therapies.
Explore everything named Acute myeloid leukemia...
